MED BRIEFS : SNX-111 CLINICAL TRIAL TO TEST NEW THERAPY AGAINST SEVERE CHRONIC CANCER PATIENTS Source: CANCER COMMUNICATION NEWSLETTER, Volume 12, Number 4, September 1996
Do you know someone who suffers from chronic pain relating to cancer? They may be eligible to participate in new study to evaluate a treatment for controlling chronic pain.
The new drug, SNX-111 has shown promise in preliminary studies of
controlling severe pain with
Side-effects appear to be mild eye jitters and a slight drop in blood pressure.
The new drug is isolated from the venom of cone snails and is a new
type of neuron-specific calcium
The study is sponsored by a biopharmaceutical company and has been
reviewed by the Food and
Severe pain not only has a profound affect on a cancer patient's
quality of life, it can also affect
For terminally ill patients, a recent study found that half of these
patients spend their final days in
The problems facing cancer patients today is that doctors have few
weapons against severe chronic
Patients who are at least 18 years of age, have chronic pain related
to cancer or HIV and have
For more information about the study, you may call 1-800-57-STUDY, extension 96.
Editor's Note: Publication of this article does not constitute an endorsement.
At the conclusion of the study and if proof of efficacy is shown, we will certainly advocate its use.
Do you have any positive comments or/and questions ? Please send to Dr. Bruce Livett
Copyright © 1998 Dynamix@WORK! All rights reserved. Last updated on December 17, 2003.